|

Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer

RECRUITINGSponsored by AstraZeneca
Actively Recruiting
SponsorAstraZeneca
Started2025-08-20
Est. completion2026-08-11
Eligibility
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07070128

Summary

It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breast cancer.

Eligibility

Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* female patients,
* aged 18 years or older,
* identified as high genetic risk by breast surgeons,
* referred to a geneticist, and
* who agree to participate in the study.

Exclusion Criteria:

* male patients,
* absence of complete information in the medical records,
* patients unaware of their biological family history, and
* patients who do not agree to participate in the study.

Conditions3

Breast CancerBreast NeoplasmsCancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.